In addition to advancing our own clinical pipeline in oncology, Cristal Therapeutics has forged a number of strategic partnerships with pharmaceutical and biotechnology companies to co-develop therapeutic nanomedicines and assess their applicability across a number of therapeutic areas.
We plan to partner / out-license CPC634, our lead product candidates after Phase 2 studies to pharmaceutical companies with late stage development and commercialisation capabilities in attractive geographic territories.
In addition CPC289, the therapeutic asset from our inflammation program is ready for pre-clinical development and is available for out-licensing.
To find out more about partnering opportunities,
or use the form below.